Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
FDA sends Sandoz warning letter
On August 12, FDA issued a warning letter to Novartis's Sandoz generic unit. The letter focused on manufacturing processes for a blood pressure medication. According to the letter, the manufacturing process did not undergo proper validation and FDA therefore questioned whether further distributing the product was prudent given the lack of solid process controls. The manufacturing process in question was for a generic version of Toprol XL, made by AstraZeneca.
The FDA said in its letter that it also had concerns about how the problems it found in process validation might affect other products the company has.
A spokesperson for Novartis said the company is working with FDA to address the concerns in the warning letter, which the spokesperson says were mainly about "documentation and validation."
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


